Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: "There is no mention of cost. The story could have at least reported what the drug costs in its current use against blood cancer. The story did a good job of explaining both the potential benefits and harms of the drugs. This was a particular strength of this story – and made it stand out in comparison with the LA Times blog story that we also reviewed. Harms were emphasized from the outset – even in the headline – in the AP story but were never mentioned in the LA Times story. And this story reminded readers of the side effects encountered with another MS drug, Tysabri. Outstanding job on this issue by the AP. The story did a very good job of explaining the studies. There is no sign of disease-mongering in this story. Two apparently independent sources were quoted. The story did a good job comparing the new drugs with existing approaches to treat MS. Story explains that the drug is already sold to treat a rare blood cancer and stated that ""it’s too soon to know if the pills will be approved by the government or widely adopted by physicians."" It does not report, however, as the LA TImes blog did, that ""The drug company MD Serono, an affiliate of Merck, has requested approval from the Food and Drug Administration to market the tablet. However it recently received a ""refuse to file"" letter from the FDA, which means the agency is requiring additional information or data. MD Serono said it is pursuing the matter with the FDA and hopes to re-submit its application."" We think that’s a crucial piece of information that affects availability, although, of course, doctors can still prescribe it for off-label use even before the FDA acts on the new request. The novelty of ""tests of the first two oral drugs developed for treating MS"" was clear in the story. It is clear that this story did not rely on a news release." Claim: MS pills show promise and risk, studies say
Example Output: Nice job explaining harms and benefits – including putting the potential risks/harms right in the headline. The appeal of an oral drug for MS is clear. The risks emphasized in this story, though, raise important questions

Example Input: Paragraph: Democrats on a subcommittee of the House of Representatives Committee on Oversight and Reform released a cache of internal Juul emails and other documents that committee staff described as early attempts to “enter schools and convey its messaging directly to teenage children.”   Juul’s use of social media influencers to promote its vaping devices in the years after it launched in 2015 also came under scrutiny. James Monsees, Juul’s co-founder and chief product officer, told the committee that the company’s target audience from the beginning has been adult cigarette smokers. Among efforts cited in the Juul documents released were a $134,000 payment to set up a five-week “holistic health education” summer camp at a Maryland charter school, recruiting children from third through 12th grades, and offering $10,000 to schools using the company’s “youth prevention and education” programs for students, including those caught using e-cigarette products. “You don’t think that sounds strange at all?” Representative Katie Hill, a Democrat, asked Juul’s chief administrative officer, Ashley Gould. “All of these educational efforts were intended to keep youth from using the product,” Gould responded. When Juul realized how the school involvement could be perceived as negative, “we stopped the program,” she said. In a statement after the hearing, Juul said the $134,000 donation was to “facilitate already-existing community outreach and youth-prevention programs,” and said the company “did not have any direct interaction with the students.”  Several committee members said Juul’s initiatives appeared similar to past efforts by the tobacco industry to reach young people under the guise of smoking prevention programs. Gould said Juul, which is 35 percent owned by Marlboro maker Altria Group Inc (MO.N), halted its program last year once it became aware of the tobacco industry’s past moves. Caleb Mintz, 17, a New York city high school student, testified at a separate hearing on Wednesday that a Juul representative came to his school as part of an educational program on mental health and addiction last year. He said in an interview Thursday that students received “mixed messages” about the product, being told it was safe but not to buy it. Mintz said after the hearing that the Juul presentation seemed to be “playing to the side of teens as rebellious. When a teen is told not to do something, they’re more likely to do it.”    Members of the committee also quizzed Gould and Monsees over the use of social media influencers to promote Juul’s vaping devices. Company executives early on agreed that “younger consumers age 25 to 34 was going to be the target of our initial campaign,” Monsees said. “They would be more receptive to new technology solutions,” such as the Juul device. Amid an enormous uptick in teenage use of e-cigarettes in 2018 — a 78% increase among high school students from 2017 to 2018, according to federal data — Juul said it ended all social media advertising last fall. Juul also pulled many flavored nicotine pods, except mint, menthol and tobacco, from retail stores, which Monsees said represented more than half of the company’s sales at that time. Claim: U.S. lawmakers grill e-cigarette maker Juul over efforts targeted at schoolchildren.
Example Output: E-cigarette maker Juul Labs Inc funded a “holistic health education” camp as part of efforts to market directly to school-aged children, members of a U.S. congressional panel said on Thursday, citing internal company documents.

Example Input: Paragraph: The pill, called the PillCam Colon, may be used for detection of colon polyps in patients after an incomplete optical colonoscopy, the Israeli medical device maker said. There are 750,000 patients in the United States alone who experience an incomplete colonoscopy each year, Given Imaging said, and they often incur additional costs, along with the inconvenience and risk associated with other procedures to complete the colorectal examination. Given Imaging is a developer of technology for visualizing, diagnosing and monitoring the digestive system, including its PillCam, a swallowed capsule endoscope. In December, medical device maker Covidien PLC said it would acquire Given Imaging for $860 million. The transaction is expected to be completed by March 31. Claim: Given Imaging gets FDA clearance for colon camera pill.
Example Output:
Camera-in-a-pill maker Given Imaging said on Monday it received U.S. Food and Drug Administration clearance for a pill to provide visualization of the colon that has a global market of 3 million procedures a year.